Tech Company Financing Transactions

Alladapt Immunotherapeutics Funding Round

Patient Square Capital, AllerFund and Gurnet Point Capital invested in a $119 million funding round for Alladapt Immunotherapeutics. The financing round closed on 6/22/2022.

Transaction Overview

Company Name
Alladapt Immunotherapeutics
Announced On
6/22/2022
Transaction Type
Venture Equity
Amount
$119,000,000
Round
Undisclosed
Investors

Patient Square Capital (Lead Investor) (Jim Momtazee)

AllerFund

Gurnet Point Capital (Sophie Kornowski)

Novartis Venture Fund

Red Tree Venture Capital

WestRiver Capital

Proceeds Purpose
Proceeds from this funding round will support the ongoing clinical development of ADP101, the Company's lead product candidate, as well as preparation for a potential pivotal trial, the continued buildout of Alladapt's manufacturing facility, and investment in further pipeline expansion.

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
405 El Camino Real 611
Menlo Park, CA 94025
USA
Phone
650-420-3900
Website
www.alladapt.com
Email Address
Not Recorded
Overview
We are dedicated to developing and commercializing effective and broadly applicable interventions for food allergy. Food allergy is a disease of the immune system that is triggered by an exceptionally broad range of commonly allergenic foods such as cow's milk, eggs, tree nuts, peanuts, shellfish and even sesame.
Profile
Alladapt Immunotherapeutics LinkedIn Company Profile
Social Media
Alladapt Immunotherapeutics Company Twitter Account
Company News
Alladapt Immunotherapeutics News
Facebook
Alladapt Immunotherapeutics on Facebook
YouTube
Alladapt Immunotherapeutics on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Ashley Dombkowski
  Ashley Dombkowski LinkedIn Profile  Ashley Dombkowski Twitter Account  Ashley Dombkowski News  Ashley Dombkowski on Facebook
Chief Financial Officer
Glenn Reicin
  Glenn Reicin LinkedIn Profile  Glenn Reicin Twitter Account  Glenn Reicin News  Glenn Reicin on Facebook
Chief Medical Officer
Dana McClintock
  Dana McClintock LinkedIn Profile  Dana McClintock Twitter Account  Dana McClintock News  Dana McClintock on Facebook
Chief Technical Officer
Michael Holfinger
  Michael Holfinger LinkedIn Profile  Michael Holfinger Twitter Account  Michael Holfinger News  Michael Holfinger on Facebook
Controller
Sid Reddy
  Sid Reddy LinkedIn Profile  Sid Reddy Twitter Account  Sid Reddy News  Sid Reddy on Facebook
Vice President
Nusrat Rabbee
  Nusrat Rabbee LinkedIn Profile  Nusrat Rabbee Twitter Account  Nusrat Rabbee News  Nusrat Rabbee on Facebook
Vice President
Mei-Lun Wang
  Mei-Lun Wang LinkedIn Profile  Mei-Lun Wang Twitter Account  Mei-Lun Wang News  Mei-Lun Wang on Facebook
VP - Manufacturing
Jim Kirchner
  Jim Kirchner LinkedIn Profile  Jim Kirchner Twitter Account  Jim Kirchner News  Jim Kirchner on Facebook
VP - Operations
Amelia Milani
  Amelia Milani LinkedIn Profile  Amelia Milani Twitter Account  Amelia Milani News  Amelia Milani on Facebook
VP - Operations
Amy Sullivan
  Amy Sullivan LinkedIn Profile  Amy Sullivan Twitter Account  Amy Sullivan News  Amy Sullivan on Facebook

 

 

Browse more venture capital transactions:

Prev: 6/22/2022: Vergo venture capital transaction
Next: 6/22/2022: Appsmith venture capital transaction

 

Share this article

 

Where The Data Comes From

We do our best to record tech company VC transactions. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.